Effects of anti TNF α antibody (infliximab) plus MTX on SCID-HuRAg-pit model

本研究通过将类风湿性关节炎（RA）滑膜组织移植于SCID小鼠背部的牙本质切片上建立了SCID-HuRAg-pit模型，探讨了英夫利昔单抗单独或英夫利昔单抗联合甲氨蝶呤（MTX）对SCID-HuRAg-pit模型的影响。英夫利西单抗给药采用渗透泵给药。甲氨蝶呤口服给药，每周3次。对照组给予人IgG。移植后4周取移植的滑膜组织，测量窝形成。同时测定血浆TNF-α、IL-6水平。血浆TNF-α和IL-6浓度在英夫利西单抗给药组中降低。但是，在牙本质上的窝形成的数量上没有显著的发现。另一方面，在英夫利西单抗联合MTX的情况下，在牙本质上的窝形成的数量方面存在显著差异。这些结果表明，抗TNF-α抗体和MTX联合使用可有效抑制骨破坏。

We already developed SCID-HuRAg-pit model which is dentin slice are engrafted with rheumatoid arthritis (RA) synovial tissues on back of SCID mice.In this study, we investigate effects of infliximab alone or infliximab plus methotrexate (MTX) for SCID-HuRAg-pit model. Administration of infliximab was using by osmotic pump. Methotrexate was administered orally 3 times per week. Control group was administrated human IgG. The engrafted synovial tissues were taken 4 weeks after transplantation and measured pit-formation. Moreover, plasma TNF-a, IL-6 were also measured. Plasma TNF-a and IL-6 concentrations were decreased in the group of infliximab administrated. However, there is no significant finding on the number of pit-formation on dentin. On the other hand, in case of infliximab plus MTX were significant differences about the number of pit-formation on dentin. These results suggest that the anti TNF-α antibody and MTX combination was useful against inhibition of bone destruction.